Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3

Notes

original target text: Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)

This mechanism refers to a fixed combination targeting three separate receptors involved in chronic obstructive airway disease: the glucocorticoid receptor, the beta-2 adrenergic receptor, and the muscarinic M3 receptor. Airway obstruction in diseases such as chronic obstructive pulmonary disease and asthma arises from several overlapping processes: chronic inflammation of the airway lining, tightening of the smooth muscle that wraps the airways, and excess mucus production. Glucocorticoid receptor agonists (inhaled corticosteroids) dampen inflammatory gene activity in airway tissue. Beta-2 adrenergic receptor agonists relax airway smooth muscle by promoting a signaling cascade that favors relaxation. Muscarinic M3 receptor antagonists block a nerve-driven signal that would otherwise cause smooth muscle contraction and mucus gland secretion. Combining agents against all three receptors in one inhaled regimen addresses inflammation and two distinct bronchoconstriction pathways simultaneously, an approach used when disease is not adequately controlled by a single class. This class of triple therapy is broadly relevant to advanced or poorly controlled obstructive lung disease, where multiple pathological processes contribute together to breathlessness, airflow limitation, and exacerbation risk.